Evidence map›Paper›PMID 39000534›Full record

ArticleInternational journal of molecular sciences2024

Synthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments.

Etelka Ferenczi, Péter Keglevich, Bizhar Ahmed Tayeb, Renáta Minorics, Dávid Papp, Gitta Schlosser, István Zupkó, László Hazai, Antal Csámpai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Etelka FerencziDepartment of Organic Chemistry, Eötvös Loránd University (ELTE), Pázmány P. sétány 1/A, H-1117 Budapest, Hungary.
Péter KeglevichDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
Bizhar Ahmed TayebInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0001-5197-564X
Renáta MinoricsInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0001-9685-813X
Dávid PappHevesy György PhD School of Chemistry, Pázmány P. sétány 1/A, H-1117 Budapest, Hungary.ORCID 0000-0002-2006-7777
Gitta SchlosserMTA-ELTE Lendület Ion Mobility Mass Spectrometry Research Group, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter sétány 1/A, H-1117 Budapest, Hungary.ORCID 0000-0002-7637-7133
István ZupkóInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0003-3243-5300
László HazaiDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
Antal CsámpaiDepartment of Organic Chemistry, Eötvös Loránd University (ELTE), Pázmány P. sétány 1/A, H-1117 Budapest, Hungary.ORCID 0000-0003-2107-7309

Funding

ELTE Thematic Excellence Programme Synth+ 1117European Union (Széchenyi Plan Plus, National Laboratory Program, PharmaLab) RRF-2.3.1-21-2022-00015Hungarian Scientific Research Fund K_129037Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund TKP2021-EGA-32
6 · The paper itself

Abstract

In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer), and SH-SY5Y (neuroblastoma) as well as on human embryonal lung fibroblast cell line MRC-5, which served as a reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (

Indexed as

AlkynesAntineoplastic AgentsCell ProliferationVinblastineCell Line, TumorDrug Screening Assays, AntitumorHeLa CellsHumansStructure-Activity RelationshipAlkynesAntineoplastic AgentsVinblastinevindolineantiproliferative effectchalconeerlotinibhybrid moleculesimatinibovarian cancerselectivitySonogashira reactionvindoline

Identifiers

PMID39000534
PMCPMC11242353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.